Search
01/01/2023
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Dickinson M.J., Barba P., Jäger U., Shah N.N., Blaise D., Briones J., Shune L., Boissel N., Bondanza A., Mariconti L., Marchal A.-L., Quinn D.S., Yang J., Price A., Sohoni A., Treanor L.M., Orlando E.J., Mataraza J., Davis J., Lu D., Zhu X., Engels B., Moutouh-de Parseval L., Brogdon J.L., Moschetta M., Flinn I.W.. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery. 2023; 13(9)DOI:10.1158/2159-8290.CD-22-1276. PMID:37249512. IF:30.600(Q1/1D).
01/01/2023
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study
Solano C., Castro-Rebollo P., Pérez-Martínez A., López-Corral L., Barba-Suñol P., Kwon M., Ortiz V., Sanz-Caballer J., Caballero A.C., Martínez J., Cedillo Á., Sureda A.. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study. BMJ Open. 2023; 13(7)DOI:10.1136/bmjopen-2022-071371. PMID:37491085. IF:2.400(Q1/3D).
01/01/2023
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Muñoz A., Ay C., Grilz E., López S., Font C., Pachón V., Castellón V., Martínez-Marín V., Salgado M., Martínez E., Calzas J., Ortega L., Rupérez A., Salas E., Pabinger I., Soria J.M.. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(16)DOI:10.1200/JCO.22.00255. PMID:36730884. IF:42.100(Q1/1D).
01/01/2023
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
García-Calderón C.B., Sierro-Martínez B., García-Guerrero E., Sanoja-Flores L., Muñoz-García R., Ruiz-Maldonado V., Jimenez-Leon M.R., Delgado-Serrano J., Molinos-Quintana Á., Guijarro-Albaladejo B., Carrasco-Brocal I., Lucena J.-M., García-Lozano J.-R., Blázquez-Goñi C., Reguera-Ortega J.L., González-Escribano M.-F., Reinoso-Segura M., Briones J., Pérez-Simón J.A., Caballero-Velázquez T.. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1152498. PMID:37122702. IF:5.700(Q1/3D).
01/01/2023
Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population
Olive-Gadea, M, de la Ossa, NP, Jovin, T, Abilleira, S, Jimenez, X, Cardona, P, Chamorro, A, Flores, A, Silva, Y, Purroy, F, Marti-Fabregas, J, Rodriguez-Campello, A, Zaragoza, J, Krupinski, J, Canovas, D, Choco, MG, Mas, N, Palomeras, E, Cocho, D, Aragones, JM, Repullo, C, Sanjurjo, E, Carrion, D, Catena, E, Costa, X, Almendros, MC, Barcelo, M, Monedero, J, Rybyeva, M, Diaz, G, Ribo, M. Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221093523. PMID:35373657. IF:6.300(Q1/1D).
01/01/2023
First pass effect in posterior circulation occlusions: Analysis from the CICAT registry
Terceno, M, Silva, Y, Bashir, S, Chamorro, A, de la Ossa, NP, Hernandez-Perez, M, Castano, C, Camps-Renom, P, Wenger, D, Cardona, P, Molina, C, Rodriguez-Campello, A, Canovas, D, Purroy, F, Salvat-Plana, M, Serena, J. First pass effect in posterior circulation occlusions: Analysis from the CICAT registry. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221089772. PMID:35272563. IF:6.300(Q1/1D).